Prescription drug advertising is facing renewed scrutiny from the FDA and bipartisan lawmakers, Axios reports
Importance
Level 1
- The FDA says many ads and social media posts fail fair-balance standards, though tougher rules could face industry resistance and First Amendment challenges
- Proposals range from tighter enforcement and pre-screening, to tax penalties or an outright ban